SLC5A2 and type 2 diabetes mellitus: The cardiovascular trials of SGLT2 inhibitors in type 2 diabetes discussed in Section 3 have generally adopted MACE as the primary safety and/or efficacy endpoint, which tends to emphasize ischemic endpoints but not heart failure events.